ArticleBritish journal of cancer2010

Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.

C PortaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.